Gallbladder and biliary disease Several meta-analyses have found that GLP-1 agonists carry a modest increase in the risk of gallbladder or biliary disease (such as gallstones and cholecystitis), especially at higher doses, over longer durations, and when used mainly for weight loss [3]
Our team at The Peer Group will continue to monitor and evaluate each patients progress all while providing ongoing support and monitoring throughout their weight loss journey
Ive taken semaglutide before and I know what the effects are and how it feels and this is not it
Unlock solutions with a local weight loss doctor to evaluate treatment plans suited to your needs
The panel helps detect potential side effects early, tracks medication response, and ensures optimal therapeutic outcomes (American Diabetes Association 2025)
This can accelerate adoption, particularly if insurance coverage is slow to catch up